{"id":"tlk286-in-combination-with-carboplatin","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Vomiting"},{"rate":"5-20%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Anorexia"},{"rate":"5-20%","effect":"Weight loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Histone deacetylases are enzymes that remove acetyl groups from histones, leading to chromatin compaction and reduced gene expression. By inhibiting these enzymes, TLK286 promotes a more open chromatin structure, allowing for increased gene expression and ultimately leading to the inhibition of cancer cell growth and induction of apoptosis.","oneSentence":"TLK286 is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the inhibition of cancer cell growth and induction of apoptosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:09.457Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT00088556","phase":"PHASE1, PHASE2","title":"Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Telik","startDate":"2004-08","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":100},{"nctId":"NCT00102973","phase":"PHASE3","title":"TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer","status":"COMPLETED","sponsor":"Telik","startDate":"2004-12","conditions":"Ovarian Neoplasms","enrollment":244},{"nctId":"NCT00051948","phase":"PHASE1, PHASE2","title":"TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Telik","startDate":"2003-01","conditions":"Ovarian Neoplasms","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TLK286 in Combination with Carboplatin","genericName":"TLK286 in Combination with Carboplatin","companyName":"Telik","companyId":"telik","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TLK286 is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the inhibition of cancer cell growth and induction of apoptosis. Used for Metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}